MINT-LEUCOVORIN 5 MG
LEUCOVORIN (LEUCOVORIN CALCIUM) : 5 MG · DIN 02496828 · MINT PHARMACEUTICALS INC
Health Canada status: MARKETED
What is MINT-LEUCOVORIN?
MINT-LEUCOVORIN 5 MG contains LEUCOVORIN (LEUCOVORIN CALCIUM) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02496828, held by MINT PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MINT-LEUCOVORIN used for?
Diminishing toxicity/counteracting impaired methotrexate elimination; treatment of megaloblastic anemias due to folate deficiency (sprue, nutritional deficiency, pregnancy, infancy).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02496828 |
|---|---|
| Brand name | MINT-LEUCOVORIN |
| Generic / active ingredient | LEUCOVORIN (LEUCOVORIN CALCIUM) : 5 MG |
| Manufacturer | MINT PHARMACEUTICALS INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | V03AF03 CALCIUM FOLINATE |
| AHFS class | 91:04.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Jan-2021 |
| Original market date | 2021-01-12 00:00:00 |
How is it administered?
Rescue: 15 mg every 6 hours for 10 doses starting 24h after methotrexate. Megaloblastic anemia: up to 15 mg daily. Oral doses >25 mg not recommended due to saturable absorption.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 missing specific temp), but typically 15-30°C.
How is it supplied?
HDPE bottles of 24 and 100 tablets.
Contraindications
Hypersensitivity to the drug or excipients; Pernicious anemia or other megaloblastic anemias where Vitamin B12 is deficient.
Warnings and precautions
Serious: Use only under expert supervision. Risk of fatal GI toxicity, myelosuppression, and SJS/TEN. May enhance 5-FU toxicity. May mask Vitamin B12 deficiency.
Is CALCIUM FOLINATE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by PFIZER CANADA ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code V03AF03 CALCIUM FOLINATE. 9 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP LEUCOVORIN | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02548208 |
| LEDERLE LEUCOVORIN | 5 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02170493 |
| LEUCOVORIN CALCIUM INJECTION | 10 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02087316 |
| LEUCOVORIN CALCIUM INJECTION | 10 MG | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02480042 |
| LEUCOVORIN CALCIUM INJECTION | 1000 MG / 100 ML | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02496925 |
| LEUCOVORIN CALCIUM INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02182998 |
| LEUCOVORIN CALCIUM INJECTION USP | 10 MG | Solution | PFIZER CANADA ULC | MARKETED | DIN 02183005 |
| RIVA LEUCOVORIN | 5 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 02493357 |
| LEDERLE LEUCOVORIN - LIQ IM IV 10MG/ML | 10 MG | LIQUID | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | DIN 02170485 |
| LEDERLE LEUCOVORIN 350MG/VIAL | 350 MG | POWDER FOR SOLUTION | LEDERLE CYANAMID CANADA INC. | CANCELLED POST MARKET | DIN 01927442 |
Who else supplies CALCIUM FOLINATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CALCIUM FOLINATE appears in 1674 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.